EP2590626

LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE FOR RNA DELIVERY

Filed

Jul 6, 2011

Technology

Chemistry · Pharmaceuticals +1

UPC cases

EPO proceedings

Ownership history

As recorded at the EPO. Transfers made after the opposition period are recorded in national registers and may be missing here.

Hover an owner to see their dates

GlaxoSmithKline Biologicals SAsince Sep 11, 2015
Novartis AGApr 12, 2013 – Sep 11, 2015

Abstract

RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.

From the international application WO2012006378

Litigation history

Date	Case	Division	Type	Outcome	Parties
Sep 14, 2026	UPC CFI 1439/2025	The Hague LD	Counterclaim for revocation	Locked	Moderna Netherlands B.V. +15

Additional proceedings on this patent

Start 14-day free trialOutcomes, the additional proceedings and the register history.Already a user? Sign in